1832 Asset Management L.P. Has $1.85 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

1832 Asset Management L.P. grew its holdings in Hologic, Inc. (NASDAQ:HOLXFree Report) by 13.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,820 shares of the medical equipment provider’s stock after buying an additional 3,091 shares during the quarter. 1832 Asset Management L.P.’s holdings in Hologic were worth $1,845,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Victory Capital Management Inc. increased its position in shares of Hologic by 4.5% during the 4th quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock worth $361,183,000 after purchasing an additional 216,958 shares in the last quarter. Norges Bank acquired a new stake in shares of Hologic during the 4th quarter worth about $217,529,000. The Manufacturers Life Insurance Company increased its position in shares of Hologic by 117.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after purchasing an additional 1,168,564 shares in the last quarter. TD Asset Management Inc increased its position in shares of Hologic by 2.8% during the 4th quarter. TD Asset Management Inc now owns 1,897,705 shares of the medical equipment provider’s stock worth $135,591,000 after purchasing an additional 52,243 shares in the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of Hologic by 9.0% during the 3rd quarter. Hsbc Holdings PLC now owns 1,721,339 shares of the medical equipment provider’s stock worth $119,472,000 after purchasing an additional 141,542 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.4 %

Hologic stock opened at $74.51 on Monday. The company’s 50 day simple moving average is $75.60 and its 200 day simple moving average is $74.08. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The firm has a market capitalization of $17.39 billion, a price-to-earnings ratio of 38.02, a PEG ratio of 2.48 and a beta of 1.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the firm earned $1.06 EPS. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current year.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research reports. Evercore ISI raised their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Argus raised their price objective on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Get Our Latest Research Report on Hologic

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.